Repeat A2 Into B Kidney Transplantation After Failed Prior A2 Into B Transplant: A Case Report
Autor: | Nabil N. Dagher, Vasishta S. Tatapudi, Robert A. Montgomery, E.S. Min, Bruce E. Gelb, Bonnie E. Lonze |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
Reoperation Endothelium medicine.medical_treatment 030230 surgery Antibodies ABO Blood-Group System 03 medical and health sciences 0302 clinical medicine Antigen ABO blood group system medicine Humans Kidney transplantation Aged Desensitization (medicine) Transplantation Deceased donor biology business.industry Graft Survival medicine.disease Kidney Transplantation Tissue Donors Titer medicine.anatomical_structure Blood Grouping and Crossmatching Blood Group Incompatibility Immunology biology.protein 030211 gastroenterology & hepatology Surgery Antibody business |
Zdroj: | Transplantation Proceedings. 50:3913-3916 |
ISSN: | 0041-1345 |
DOI: | 10.1016/j.transproceed.2018.06.034 |
Popis: | Kidneys from donors with blood type A2 can be successfully transplanted into blood type B and O recipients without the need for desensitization if the recipient's starting anti-A hemagglutinin titer is within an acceptable range. National kidney allocation policy now offers priority for eligible B recipients to receive A2 or A2B deceased donor kidneys, and therefore, the frequency with which A2 or A2B to B transplants will occur is expected to increase. The precise mechanisms by which antibody-mediated rejection is averted in these cases despite the presence of both circulating anti-A antibody and expression of the A2 antigen on the graft endothelium are not known. Whether this process mirrors proposed mechanisms of accommodation, which can occur in recipients of ABO incompatible transplants, is also not known. Repeated exposure to mismatched antigens after retransplantation could elicit memory responses resulting in antibody rebound and accelerated antibody-mediated rejection. Whether this would occur in the setting of repeated A2 donor exposure was uncertain. Here we report the case of a patient with history of a prior A2 to B transplant which failed owing to nonimmunologic reasons; the patient successfully underwent a repeat A2 to B transplant. Neither rebound in anti-A2 antibody nor clinical evidence of antibody-mediated rejection were observed after the transplant. Current kidney allocation will likely enable more such transplants in the future, and this may provide a unique patient population in whom the molecular mechanisms of incompatible graft accommodation may be investigated. |
Databáze: | OpenAIRE |
Externí odkaz: |